Literature DB >> 6491902

Pharmacodynamic modeling of thiopental anesthesia.

D R Stanski, R J Hudson, T D Homer, L J Saidman, E Meathe.   

Abstract

We have pharmacodynamically modeled the relationship between the thiopental serum concentration and its effects on the electroencephalogram (EEG). Power spectral analysis was used to calculate the spectral edge, a measure of the underlying EEG frequency that characterizes the progressive slowing of the EEG induced by thiopental. Eight male volunteer subjects had venous thiopental serum concentrations measured, and 10 surgical patients had arterial serum concentrations measured. Thiopental was infused at a rate of 75 to 150 mg/min until a burst suppression EEG pattern was evident. Frequent blood samples were obtained during and after the infusion for measurement of serum thiopental concentrations, and the EEG was recorded for subsequent off-line power spectral analysis to calculate the spectral edge. With venous blood sampling, it was not possible to demonstrate significant hysteresis between the thiopental serum concentration and the spectral edge, allowing thiopental concentrations to be directly related to the spectral edge. With arterial blood sampling, significant hysteresis was present, requiring an effect compartment to relate concentration to effect. The half-time for equilibration (mean +/- SD) between concentration and response for the arterial data was 1.2 +/- 0.30 min. This value for Keo is consistent with known values for cerebral blood flow and thiopental brain: blood partition coefficient. Arterial-venous concentration differences cause the apparent lack of hysteresis with venous blood sampling. An inhibitory sigmoid Emax pharmacodynamic model optimally characterized the relationship between thiopental concentrations and the spectral edge. This model allows estimation of the thiopental serum concentration that causes one-half of the maximal EEG slowing (IC50), which is a measure of an individual's sensitivity to thiopental. Except for the hysteresis, there was no statistical difference in the parameters of the inhibitory sigmoid Emax pharmacodynamic model when venous and arterial blood samplings were compared. Arterial blood sampling offers some distinct advantages when pharmacodynamically modeling continuous, rapidly changing measures of drug effect, such as the EEG.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491902     DOI: 10.1007/bf01059279

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  14 in total

1.  Electro-encephalographic patterns produced by thiopental sodium during surgical operations; description and classification.

Authors:  D K KIERSEY; R G BICKFORD; A FAULCONER
Journal:  Br J Anaesth       Date:  1951-07       Impact factor: 9.166

2.  On biological assays involving quantal responses.

Authors:  D R Waud
Journal:  J Pharmacol Exp Ther       Date:  1972-12       Impact factor: 4.030

3.  A model for studying depth of anesthesia and acute tolerance to thiopental.

Authors:  R J Hudson; D R Stanski; L J Saidman; E Meathe
Journal:  Anesthesiology       Date:  1983-10       Impact factor: 7.892

Review 4.  Neurophysiologic effects of general anesthetics. I. The electroencephalogram and sensory evoked responses in man.

Authors:  D L Clark; B S Rosner
Journal:  Anesthesiology       Date:  1973-06       Impact factor: 7.892

5.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

6.  Development of a model for integrated pharmacokinetic and pharmacodynamic studies of intravenous anaesthetic agents: applications to minaxolone.

Authors:  L E Mather; L T Seow; J G Roberts; G K Gourlay; M J Cousins
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man.

Authors:  D R Stanski; J Ham; R D Miller; L B Sheiner
Journal:  Anesthesiology       Date:  1979-09       Impact factor: 7.892

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Pharmacokinetics and anesthetic potency of a thiopental isomer.

Authors:  D R Stanski; P G Burch; S Harapat; R K Richards
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

10.  Modelling theophylline response in individual patients with chronic bronchitis.

Authors:  B Whiting; A W Kelman; J Barclay; G J Addis
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

View more
  26 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions.

Authors:  J W Mandema; P Veng-Pedersen; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-12

4.  Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.

Authors:  P Francheteau; J L Steimer; C Dubray; D Lavene
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

5.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.

Authors:  J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

Review 6.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.

Authors:  B Tuk; M Danhof; J W Mandema
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

8.  A physiologically-based recirculatory meta-model for nasal fentanyl in man.

Authors:  Richard N Upton; David J R Foster; Lona L Christrup; Ola Dale; Kristin Moksnes; Lars Popper
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-19       Impact factor: 2.745

9.  Patient response to laryngeal mask insertion after induction of anaesthesia with propofol or thiopentone.

Authors:  P Scanlon; M Carey; M Power; F Kirby
Journal:  Can J Anaesth       Date:  1993-09       Impact factor: 5.063

10.  In vivo relationships between the cerebral pharmacokinetics and pharmacodynamics of thiopentone in sheep after short-term administration.

Authors:  R N Upton; G L Ludbrook; C Grant; E C Gray
Journal:  J Pharmacokinet Biopharm       Date:  1996-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.